tirzepatide kidney damage Interplay of Chronic Disease and the Effects of in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial Tirzepatide and Kidney Health: Safety

Deficiency is more common than most people assume: estimated at 12% of the US general population and considerably higher in athletes due to sweat losses

The before-and-after results you see in engaged communities consistently outperform results from isolated, unsupported use

Older adults managing age-related decline Aging brings slower healing, increased injury susceptibility, and accumulated damage from decades of activity

Recent trials have shown: Up to 20% body weight reduction with weekly GLP-1 agonists (Wilding et al., NEJM) Improvements in HbA1c, fasting glucose, and cardiovascular outcomes (Marso et al., NEJM) This drug class is now widely used for: Obesity (with or without diabetes) Type 2 diabetes PCOS-related insulin resistance Metabolic syndrome Common Side Effects and Patient Concerns Despite their benefits, GLP-1 agonists are not without risks or drawbacks